Abstract: The invention is directed to an animal feed suitable for feeding mammals, birds and fish, comprising an alkyl ester of a fatty acid, wherein said fatty acid has a chain length of 5-12 carbon atoms, and wherein the dosage of said ester in said animal feed is 50 ppm by weight or higher, based on the total weight of said animal feed.
Type:
Grant
Filed:
January 25, 2010
Date of Patent:
January 9, 2018
Assignee:
Nutreco Nederland B.V.
Inventors:
Yanming Han, Coenraad Henricus Maria Smits, John Brennan, Gregory Ian Page, Johannes Teunis Pieter Van Dam
Abstract: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.
Type:
Grant
Filed:
August 7, 2013
Date of Patent:
November 21, 2017
Assignee:
THE UNIVERSITY OF HONG KONG
Inventors:
Chi Ming Che, Raymond Wai-Yin Sun, Lok Fung Chow, Jing Yan
Abstract: The present invention includes compositions that are useful in treating, ameliorating, or preventing nerve agent poisoning. The present invention also includes methods of preventing, treating or ameliorating nerve agent poisoning in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also includes methods of preventing, treating or ameliorating a seizure induced by a disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also comprises a kit comprising compositions of the invention.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
November 14, 2017
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: Methods for killing spores include contacting the spores with an aqueous solution containing performic acid. The contacting occurs at a temperature of less than or equal to about 35° C. for a period of time of less than or equal to about 15 seconds, and the contacting effects at least a 4 log reduction in a number of spores capable of reproduction, metabolism, and/or growth.
Abstract: The invention relates to antibacterial compounds of formula I wherein R1 is H or halogen; R2 is alkynyloxy or the group M; R3 is H or halogen; M is one of the groups wherein A is a bond, CH2CH2, CH?CH or C?C and R1A, R2A, R3A, R1B and R1C are as defined in claim 1; and salts thereof.
Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.
Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.
Type:
Grant
Filed:
May 6, 2015
Date of Patent:
October 10, 2017
Assignee:
SAMI LABS LIMITED
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam, Douglas Kalman, Beena Bhat, Priti Vaidyanathan, Sarang Bani, Anjali Pandey, Suresh Karri
Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
October 10, 2017
Assignee:
Cadila Healthcare Limited
Inventors:
Bipin Pandey, Kaushik Sata, Himanshu Kothari, Pankaj R. Patel
Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) or an ortholog of AgrA includes administering to the bacterium an amount of a pharmaceutical composition effective to inhibit the synthesis of one or more virulence factors by the bacterium, the pharmaceutical composition including an AgrA antagonist.
Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.
Type:
Grant
Filed:
March 28, 2006
Date of Patent:
September 19, 2017
Assignee:
LTS Lohmann Theraple-Systeme AG
Inventors:
Markus Krumme, Albert Radlmaier, Sascha General, Michael Dittgen, Keith Jensen
Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
Type:
Grant
Filed:
April 21, 2010
Date of Patent:
September 12, 2017
Assignee:
Resverlogix Corp.
Inventors:
Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. McLure, Ewelina B. Kulikowski
Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
Type:
Grant
Filed:
March 21, 2014
Date of Patent:
September 5, 2017
Assignee:
Anacor Pharmaceuticals, Inc.
Inventors:
Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
Abstract: Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed.
Type:
Grant
Filed:
June 23, 2015
Date of Patent:
September 5, 2017
Assignee:
Dipharma Francis S.r.l.
Inventors:
Pietro Allegrini, Emanuele Attolino, Renzo Graziosi
Abstract: Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing water and one or more water-soluble organic solvents in a concentration sufficient to reduce the surface tension of the liquid to 64 dynes/cm or less. The benzoyl peroxide can then be subjected to a micronization treatment to obtain a suspension containing micronized benzoyl peroxide.
Abstract: The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.
Type:
Grant
Filed:
July 8, 2015
Date of Patent:
August 8, 2017
Assignee:
Janssen Pharmaceutica NV
Inventors:
Joannes Theodorus Maria Linders, Peter Walter Maria Roevens, Brian Joel Hrupka
Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
Type:
Grant
Filed:
June 15, 2015
Date of Patent:
August 8, 2017
Assignees:
Zinfandel Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
Abstract: The present invention relates to compounds of formula (I) wherein Q is Q1 or Q2 P is P1, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, Y1, Z, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.
Type:
Grant
Filed:
January 31, 2011
Date of Patent:
July 25, 2017
Assignee:
Syngenta Participations AG
Inventors:
Myriem El Qacemi, Jerome Yves Cassayre, Julie Clementine Toueg, Peter Renold, Thomas Pitterna
Abstract: Provided are biocide compositions and bleach compositions comprising organic acyl polyoxychlorine and related methods. The reduction of the acyl polyoxychlorine group releases a reactive intermediate that undergoes a series of cascading reduction steps, resulting in termination products Generally Recognized As Safe.
Abstract: Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using crystal engineering is underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (i.e. lithium salicylate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.